StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Free Report) in a research report sent to investors on Wednesday. The brokerage issued a sell rating on the stock.
Ayala Pharmaceuticals Stock Performance
ADXS opened at $0.26 on Wednesday. Ayala Pharmaceuticals has a twelve month low of $0.14 and a twelve month high of $1.95. The firm’s 50-day simple moving average is $0.38 and its 200-day simple moving average is $0.59. The firm has a market cap of $2.82 million, a price-to-earnings ratio of -0.03 and a beta of 1.45.
Ayala Pharmaceuticals (NASDAQ:ADXS – Get Free Report) last issued its quarterly earnings data on Tuesday, April 16th. The company reported ($2.96) EPS for the quarter.
Ayala Pharmaceuticals Company Profile
Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.
Featured Articles
- Five stocks we like better than Ayala Pharmaceuticals
- What is Forex and How Does it Work?
- Sarepta Therapeutics Stock Soars on FDA Approval
- Short Selling: How to Short a Stock
- CarMax: A Market Melt-Up Waiting to Happen for this Stock
- Trading Stocks: RSI and Why it’s Useful
- 3 Solar Stocks to Watch that are Building the Green Energy Future
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
